A recent study suggests that people who discontinue new GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who end conventional diet and exercise plans.
Findings released in a prominent health publication points out that while overweight people often shed substantial amounts of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using such drugs should be aware of the risk of rapid rebound weight gain when the therapy is stopped," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a return to original mass in about 18 months.
Comparing Approaches
The analysis, which looked at dozens of studies involving thousands of participants, contrasted the results of the injectable medications with older methods.
Researchers emphasize that people who shed pounds through diet and exercise usually experience a slower creep back—around 0.1 kg a month—after stopping.
Explaining the Fast Regain
Doctors suggest the mechanism of the jabs is key to understanding the heightened regain.
The injections imitate a natural hormone called GLP-1, which helps regulate hunger.
"Artificially providing GLP-1 levels several times higher than normal could lead to the system to produce less of its own natural GLP-1, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication means appetite is no longer kept in check, making binge eating a significant risk."
A Chronic Disease?
Medical guidelines recommend the injections for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, considering the significant potential of relapse, the therapy should be considered long-term.
This perspective is echoed by pharmaceutical companies, who note that the results "underscore the persistent nature of obesity," akin to managing conditions like high blood pressure.
User Testimonies
Users who have come off the medication report a sudden resurgence of cravings.
"It was like a switch flipping and you become ravenous," recalled one woman.
This challenge is worsened if patients have not developed permanent lifestyle or habit modifications during therapy.
Significant Adoption
Figures show that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is greater among females than men.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a magic cure and long-term success hinges on combined behavioural management.
